Placental membrane preparations and methods of making and using same for regenerating cartilage and spinal intervertebral discs
A method for treating cartilage defects including providing a placental membrane preparation that includes ground or minced placental membranes and optionally, a ground or minced cartilage and/or biocompatible glue, and introducing the preparation to a cartilage defect within a skeletal joint. The cartilage defect may include a hyaline cartilage defect, such as a chondral defect, or meniscal defect. The treatment may be provided in combination with other treatments such as marrow stimulation treatments and surgical repair treatments using sutures or other fixation techniques. The preparation promotes the regeneration of cartilage within the skeletal joint.
1. A method of generating cartilage in vivo in a skeletal joint comprising,
cryopreserving a combination including amniotic fluid cells and a ground placental membrane material in a cryopreservative solution containing 5% to 10% by volume dimethyl sulfoxide and 15% to 25% by volume protein with a balance of crystalloids,
forming a preparation from the combination, the preparation including the amniotic fluid cells and the placental membrane material, and
applying the preparation to a cartilage defect preparation to generate hyaline cartilage within the skeletal joint in vivo.
2. The method according to claim 1 comprising adding to the preparation a processed cartilage selected from the group consisting of a ground cartilage, a minced cartilage, a cartilage paste and combinations thereof.
3. The method according to claim 2 wherein the processed cartilage is selected from the group consisting of an autograft cartilage, an allograft cartilage and combinations thereof.
4. The method according to claim 1 comprising adding to the preparation hyaluronic acid, saline or a combination thereof.
5. The method according to claim 1 wherein the ground placental membrane material exhibits an average particle size of less than 0.1 mm.
6. The method according to claim 1 wherein the preparation includes the minced placental membrane and the minced placental membrane exhibits an average particle size within a range of 0.1 mm to 3 mm.
7. The method according to claim 1 wherein the placental membrane material includes amnion tissue containing organized amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors contained within the ECM and amniotic tissue cells.
8. The method according to claim 7 wherein the ECM includes amnion-derived collagen, fibronectin, laminin, proteoglycans and glycosaminoglycans.
9. The method according to claim 8 wherein the amnion-derived collagen is derived from an epithelium layer, a basement membrane layer, a compact layer, a fibroblast layer, an intermediate layer and a spongy layer of the amnion tissue.
10. The method according to claim 1 wherein the preparation is injected into the cartilage defect.
11. The method according to claim 1 wherein the preparation is introduced to the cartilage defect using a minimally invasive procedure or through an arthroscopic cannula.
12. The method according to claim 1 wherein the preparation is injected into a joint capsule of the skeletal joint after a marrow stimulation procedure has been performed for stimulating the development of a reparative cartilage in the skeletal joint.
13. The method according to claim 12 further comprising, following injecting the preparation into the joint capsule, evaluating the amount of in vivo cartilage generation within the skeletal joint, and based thereon, determining whether additional injections of the preparation into the joint capsule are desired for accomplishing a desired amount of in vivo cartilage generation within the skeletal joint.
14. The method according to claim 1 comprising adding to the preparation a biocompatible glue.
15. The method according to claim 1 wherein the cartilage defect is a hyaline articular cartilage defect.
16. The method according to claim 1 further comprising causing blood to accumulate within the cartilage defect.
17. The method according to claim 16 wherein the blood forms a clot within the cartilage defect.
18. The method according to claim 16 wherein the blood originates from subchondral bone located adjacent to the cartilage defect.
19. The method according to claim 16 wherein the preparation is introduced to the cartilage defect following accumulation of the blood within the cartilage defect.
20. The method according to claim 1 further comprising performing a marrow stimulation technique in the skeletal joint.
21. The method according to claim 1 wherein the cartilage defect is a meniscus cartilage defect.
22. The method according to claim 1 wherein the preparation excludes in vitro cultured cells.
23. The method according to claim 1 wherein the preparation excludes in vitro cultured chondrocytes.
24. The method according to claim 1 wherein the preparation promotes the regeneration of cartilage in the cartilage defect in the absence of in vitro cultured cells.
25. The method according to claim 1 further comprising removing diseased cartilage from the skeletal joint thereby forming a void into which the preparation is introduced.
26. The method according to claim 25 wherein substantially all of a healthy cartilage in the skeletal joint remains in the skeletal joint after the diseased cartilage is removed.
27. The method according to claim 1 wherein the preparation excludes a synthetic matrix material.
28. The method according to claim 1 wherein the preparation is substantially free of chondrocytes immediately prior to introduction to the cartilage defect.
29. The method according to claim 1 wherein a plurality of cells contained within and native to the placental membrane material chondrogenically differentiate in vivo within the cartilage defect.
30. The method according to claim 29 wherein the plurality of cells include mesenchymal cells.
31. The method according to claim 1 wherein the cartilage defect is an intervertebral disc defect.
32. The method of claim 1 comprising cryopreserving the combination.
33. The method of claim 1 comprising cryopreserving the combination in a solution containing dimethyl sulfoxide.
34. The method of claim 1 comprising cryopreserving the combination in a solution containing approximately 5% to 10% by volume dimethyl sulfoxide.
35. The method of claim 1 , wherein the cryopreservative solution contains 10% by volume dimethyl sulfoxide.
36. The method of claim 1 wherein the amniotic fluid cells are viable.
37. The method of claim 1 comprising in vivo chondrogenic differentiation of the amniotic fluid cells.